[Protective effect of ARB on vascular diseases].
Kim-Mitsuyama
Shokei
S
Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences.
D000804:Angiotensin II / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D048848:MAP Kinase Kinase Kinase 5 / Q000502:physiology; D009569:Nitric Oxide; D018384:Oxidative Stress
D047228:Angiotensin II Type 1 Receptor Blockers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000804:Angiotensin II; D009569:Nitric Oxide; D048848:MAP Kinase Kinase Kinase 5